NEW YORK & MAINZ, Germany – September 8, 2025 – Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today positive topline results from an ongoing Phase 3 clinical trial of their LP.8.1-adapted COVID-19 vaccine (2025–2026 Formula). The findings show a robust immune response and strong safety profile in adults aged 65+ and in adults 18–64 with at least one underlying risk condition.Public HealthNEW YORK & MAINZ, Germany – September 8, 2025 – Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today positive topline results from an ongoing Phase 3 clinical trial of their LP.8.1-adapted COVID-19 vaccine (2025–2026 Formula). The findings show a robust immune response and strong safety profile in adults aged 65+ and in adults 18–64 with at least one underlying risk condition.
The data reinforce preclinical evidence supporting the FDA’s recent approval of the vaccine’s updated formula, tailored for the LP.8.1 subline age of SARS-CoV-2. Both companies have submitted the results to the FDA for regulatory follow-up.
Science Significance
The LP.8.1-adapted vaccine builds on mRNA technology first proven with COMIRNATY®. In the Phase 3 cohort, patients experienced at least a four-fold increase in neutralizing antibody titers against the LP.8.1 sublineage just 14 days post-vaccination. Importantly, the results confirm that vaccine-induced immunity can be rapidly adapted to emerging variants, ensuring relevance against evolving SARS-CoV-2 subline ages.
These findings represent another milestone in mRNA vaccine science, highlighting its flexibility to address viral evolution. With more than 5 billion doses of Pfizer-BioNTech vaccines distributed globally, the updated data add to the growing scientific record validating the platform’s ability to provide population-wide immune protection.
Regulatory Significance
Advertisement
The FDA’s approval of the 2025–2026 Formula, now bolstered by clinical trial data, strengthens regulatory confidence in adaptive vaccine frameworks. By demonstrating safety and efficacy across high-risk populations, Pfizer and BioNTech position their vaccine for continued inclusion in seasonal vaccination recommendations.
The data have been submitted to the FDA, ensuring regulators have timely and evidence-based insights into immunogenicity, tolerability, and safety. This evidence may shape future regulatory policy on variant-adapted boosters, emphasizing streamlined review pathways for mRNA vaccines targeting emerging threats.
Business Significance
For Pfizer and BioNTech, the strong data fortify their leadership in the global COVID-19 vaccine market. With vaccine demand expected to remain significant among high-risk populations, the LP.8.1-adapted formula will support revenue stability through 2026.
Pfizer has already distributed more than 5 billion doses worldwide, and BioNTech’s proprietary mRNA platform continues to enable rapid scale-up. The results not only maintain investor confidence but also ensure both companies retain their competitive advantage in next-generation infectious disease vaccines.
Patients’ Significance
For patients, particularly those aged 65+ and those with comorbidities, the topline data provide reassurance. The vaccine demonstrated no new safety concerns and showed strong protection against a challenging new sublineage, which is crucial for populations most at risk of severe COVID-19.
The findings also inform healthcare providers by giving early clinical insights ahead of the 2025–2026 vaccination season. For patients, this means greater protection, improved outcomes, and confidence in receiving the updated formula.
Policy Significance
The positive data may influence public health policy across the U.S., EU, and other jurisdictions. By providing concrete evidence that variant-adapted vaccines can deliver enhanced immunity in high-risk groups, policymakers may move toward annual vaccination strategies akin to seasonal influenza campaigns.
The trial also supports global vaccine equity goals, as adaptive mRNA technology ensures timely development and distribution of vaccines targeted against evolving variants, aligning with WHO’s pandemic preparedness objectives.
Transaction Highlights
In the Phase 3 clinical trial cohort, 100 participants were enrolled, including 50 adults aged 65 and older and 50 adults aged 18–64 with at least one underlying risk factor for severe COVID-19. All participants had previously received the KP.2-adapted vaccine at least six months prior and had not been infected with COVID-19 during that period. After receiving a 30-µg dose of the LP.8.1-adapted COVID-19 vaccine (2025–2026 Formula), participants demonstrated a robust immune response, with neutralizing antibody titers against the LP.8.1 subline age increasing by at least four-fold compared to pre-vaccination levels. The immune boost was observed across both age groups just 14 days post-vaccination. Importantly, the safety profile remained consistent with prior formulations, and no new safety signals were identified, reinforcing the vaccine’s tolerability. These findings not only confirm the preclinical data that supported the recent FDA approval but also provide critical early insights for prescribers as the 2025–2026 vaccination season begins.
Source: Pfizer Inc Press Release
